	UNITED STATES	OMB APPROVAL
	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number: 3235-0582
		Expires: May 31, 2021
		Estimated average burden hours per response........7.2

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number 811- 06565

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA		02110
(Address of principal executive offices)		(Zip code)

Laura Woodward
Tekla Life Sciences Investors
100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant’s telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 7/1/18-6/30/19

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

HQL Vote Summary

AC IMMUNE SA

Security	H00263105	Meeting Type	Annual
Ticker Symbol	ACIU	Meeting Date	28-Jun-2019
Record Date	23-May-2019

Item	Proposal	Proposed by	Vote	For/Against Management
A.	In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors.	Management	For
1.	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2018.	Management	For
2.	Appropriation of Loss.	Management	For
3.	Discharge of the Members of the Board of Directors and the Executive Committee.	Management	For
4a.	Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2019 to 30 June 2020.	Management	For
4b.	Vote on Equity for Members of the Board of Directors.	Management	For
4c.	Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2019 to 30 June 2020.	Management	For
4d.	Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2019.	Management	For
4e.	Vote on Equity for Members of the Executive Committee.	Management	For
5a.	Re-election of Douglas Williams as member and election as Chairman of the Board of Directors.	Management	For
5b.	Re-election of Martin Velasco as member and election as Vice- Chairman of the Board of Directors.	Management	For
5c.	Re-election of Peter Bollmann as Members of the Board.	Management	For
5d.	Re-election of Friedrich von Bohlen as Members of the Board.	Management	For
5e.	Re-election of Andrea Pfeifer as Members of the Board.	Management	For
5f.	Re-election of Tom Graney as Members of the Board.	Management	For
5g.	Re-election of Werner Lanthaler as Members of the Board.	Management	For
5h.	Election of Roy Twyman as Members of the Board.	Management	For
6a.	Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee.	Management	For
6b.	Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee.	Management	For
6c.	Re-election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee.	Management	For
7.	Election of the independent proxy Reymond & Associés, represented by Denis Cherpillod, avocat, Lausanne.	Management	For
8.	Re-election of the Auditors, PricewaterhouseCoopers SA, Pully.	Management	For
9.	Authorized Share Capital.	Management	For
10.	Conditional Capital Increase for Bonds and Similar Debt Instruments.	Management	For
11.	Conditional Capital Increase for Employee Benefit Plans.	Management	For

ACADIA PHARMACEUTICALS INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	26-Jun-2019
Record Date	29-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Laura Brege		For	For
	2	Stephen Davis		For	For
2.	To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,300,000 shares.		Management	For	For
3.	To approve an amendment to our 2004 Employee Stock Purchase Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000 shares.		Management	For	For
4.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.		Management	For	For
5.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

ACCELERON PHARMA INC.

Security	00434H108	Meeting Type	Annual
Ticker Symbol	XLRN	Meeting Date	06-Jun-2019
Record Date	09-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Tom Maniatis, Ph.D.	Management	For	For
1b.	Election of Class III Director: Richard F. Pops	Management	For	For
1c.	Election of Class III Director: Joseph S. Zakrzewski	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

ADAPTIMMUNE THERAPEUTICS PLC

Security	00653A107	Meeting Type	Annual
Ticker Symbol	ADAP	Meeting Date	02-May-2019
Record Date	15-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect as a director, John Furey, who retires in accordance with the Articles of Association.	Management	For	For
O2	To re-elect as a director, Ali Behbahani, who retires by rotation in accordance with the Articles of Association.	Management	For	For
O3	To re-elect as a director, James Noble, who retires by rotation in accordance with the Articles of Association.	Management	For	For
O4	To re-appoint KPMG LLP as auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders.	Management	For	For
O5	To authorize the Audit Committee to determine our auditors’ remuneration for the fiscal year ending December 31, 2019.	Management	For	For
O6	To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2018 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2018.	Management	For	For
O7	To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2018.	Management	For	For
O8	To indicate, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers.	Management	1 Year	For
O9	To receive and approve our U.K. statutory directors’ remuneration report for the year ended December 31, 2018.	Management	For	For
O10	To authorize the Directors under Section 551 of the U.K. Companies Act 2006 (the “2006 Act”) to allot shares or to grant rights to subscribe for or to convert any security into shares.	Management	For	For
S11	To empower the Directors to allot equity securities for cash pursuant to Section 570(1) of the 2006 Act as if Section 561(1) of the 2006 Act did not apply to that allotment.	Management	For	For

AERIE PHARMACEUTICALS, INC.

Security	00771V108	Meeting Type	Annual
Ticker Symbol	AERI	Meeting Date	23-May-2019
Record Date	26-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	G. D. Cagle, Ph.D.		For	For
	2	R. Croarkin		For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve, by a non-binding vote, the compensation of our named executive officers (“say-on-pay”).		Management	For	For

AERPIO PHARMACEUTICALS, INC.

Security	00810B105	Meeting Type	Annual
Ticker Symbol	ARPO	Meeting Date	18-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Anupam Dalal		For	For
	2	Pravin Dugel		For	For
	3	Steven Prelack		For	For
2.	To ratify the appointment of Ernst & Young, LLP as Aerpio’s independent registered accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

AFFIMED N.V

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	25-Jun-2019
Record Date	28-May-2019

Item	Proposal	Proposed by	Vote	For/Against Management
4.	Discussion of the 2018 Statutory Annual Report and proposal to adopt the financial statements for the financial year 2018, as prepared in accordance with Dutch law	Management	For	For
5.	Discharge of the managing directors for their management during the financial year 2018	Management	For	For
6.	Discharge of the supervisory directors for their supervision during the financial year 2018	Management	For	For
7.	Reappointment of Dr. Bernhard Ehmer as a supervisory director	Management	For	For
8.	Appointment of the auditor for the financial year 2019	Management	For	For
9a.	Authorization to the Management Board to issue common shares and/or grant rights to subscribe for common shares	Management	For	For
9b.	Authorization to the Management Board to restrict and/or exclude pre-emptive rights in connection with agenda item 9 a.	Management	For	For
10.	Authorization to acquire shares	Management	For	For

AGIOS PHARMACEUTICALS, INC.

Security	00847X104	Meeting Type	Annual
Ticker Symbol	AGIO	Meeting Date	29-May-2019
Record Date	08-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jacqualyn A.Fouse, PhD		For	For
	2	David Scadden, M.D.		For	For
	3	David P. Schenkein, MD		For	For
2.	To vote, on an advisory basis, to approve named executive officer compensation.		Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

AKEBIA THERAPEUTICS, INC.

Security	00972D105	Meeting Type	Special
Ticker Symbol	AKBA	Meeting Date	11-Dec-2018
Record Date	22-Oct-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1	To approve the issuance of shares of common stock, par value $0.00001 per share of Akebia Therapeutics, Inc. in connection with the merger of Alpha Therapeutics Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Akebia Therapeutics, Inc. (“Akebia”), with and into Keryx Biopharmaceuticals, Inc. (“Keryx”), as described in the Agreement and Plan of Merger.	Management	For	For
2	The Adjournment Proposal: To approve adjournments of the special meeting of stockholders from time to time, if necessary or appropriate, including to solicit additional proxies in favor of the Share Issuance Proposal if there are insufficient votes at the time of such adjournment to approve such proposal.	Management	For	For

AKEBIA THERAPEUTICS, INC.

Security	00972D105	Meeting Type	Annual
Ticker Symbol	AKBA	Meeting Date	06-Jun-2019
Record Date	12-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	John P. Butler		For	For
	2	Michael T. Heffernan		For	For
	3	Jodie P. Morrison		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	Approval of the Amended and Restated 2014 Employee Stock Purchase Plan.		Management	For	For

ALBIREO PHARMA INC.

Security	01345P106	Meeting Type	Annual
Ticker Symbol	ALBO	Meeting Date	14-Jun-2019
Record Date	17-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	David Chiswell, Ph.D.		For	For
	2	Davey S. Scoon		For	For
2.	To approve the amendment to the Albireo Pharma, Inc. 2018 Equity Incentive Plan.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as Albireo’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Annual
Ticker Symbol	ALXN	Meeting Date	14-May-2019
Record Date	15-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Felix J. Baker		For	For
	2	David R. Brennan		For	For
	3	Christopher J. Coughlin		For	For
	4	Deborah Dunsire		For	For
	5	Paul A. Friedman		For	For
	6	Ludwig N. Hantson		For	For
	7	John T. Mollen		For	For
	8	Francois Nader		For	For
	9	Judith A. Reinsdorf		For	For
	10	Andreas Rummelt		For	For
2.	Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm.		Management	For	For
3.	Approval of a non-binding advisory vote of the 2018 compensation paid to Alexion’s named executive officers.		Management	For	For
4.	Shareholder proposal requesting certain proxy access Bylaw amendments.		Shareholder	Against	For

ALKERMES PLC

Security	G01767105	Meeting Type	Annual
Ticker Symbol	ALKS	Meeting Date	22-May-2019
Record Date	21-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	To elect as Class II director to serve for a three-year term: David W. Anstice AO	Management	For	For
1.2	To elect as Class II director to serve for a three-year term: Robert A. Breyer	Management	For	For
1.3	To elect as Class II director to serve for a three-year term: Wendy L. Dixon, Ph.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company’s named executive officers.	Management	For	For
3.	To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration.	Management	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	Management	For	For

ALLIQUA BIOMEDICAL, INC.

Security	019621309	Meeting Type	Special
Ticker Symbol	ALQA	Meeting Date	08-Mar-2019
Record Date	22-Jan-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A proposal to approve the Merger, the Merger Agreement, the issuance of the Company’s common stock pursuant to the Merger Agreement and transactions contemplated by the Merger, as well as the resulting “change of control” of the Company under Nasdaq rules (the “Merger Proposal”).	Management	For	For
2.	A proposal to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s common stock (the “Reverse Stock Split Proposal”).	Management	For	For
3.	A proposal to adjourn or postpone the Special Meeting, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Merger Proposal and the Reverse Stock Split Proposal (the “Adjournment Proposal”).	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	25-Apr-2019
Record Date	01-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Margaret A. Hamburg, M.D.	Management	For	For
1b.	Election of Class III Director: Steven M. Paul, M.D.	Management	For	For
1c.	Election of Class III Director: Colleen F. Reitan	Management	For	For
1d.	Election of Class III Director: Amy W. Schulman	Management	For	For
2.	To approve an Amendment to our Restated Certificate of Incorporation to permit the holders of at least a majority of our common stock to call special meetings of the stockholders.	Management	For	For
3.	To approve an Amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock thereunder.	Management	For	For
4.	To approve an Amendment to our 2018 Stock Incentive Plan.	Management	For	For
5.	To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers.	Management	For	For
6.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2019.	Management	For	For

ALTERG, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Sep-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Coversion of All Outstanding Preferred Stock	Management	For	For
2	Reverse Stock Split and Certificate of Incorporation	Management	For	For
3	Series D Financing	Management	For	For
4	Waiver of Preemptive Right and Notice	Management	For	For
5	Increase of 2007 Stock Option Plan	Management	For	For
6	Board of Directors	Management	For	For
7	Omnibus Resolutions	Management	For	For

AMARIN CORPORATION PLC

Security	023111206	Meeting Type	Annual
Ticker Symbol	AMRN	Meeting Date	20-May-2019
Record Date	11-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Mr. Jan van Heek as a director.	Management	For	For
2.	To re-elect Ms. Kristine Peterson as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company’s “named executive officers” as described in full in the “Executive Compensation Discussion and Analysis” section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure on pages 25 to 55 of the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors’ remuneration as described in full on pages 9 to 10 of the accompanying Proxy Statement.	Management	For	For
5.	To generally and unconditionally reauthorize the Board of Directors of the Company to exercise all powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares of the Company up to an aggregate nominal amount of GBP 148,000,000 (being the aggregate nominal amount of GBP 125,000,000 in respect of ordinary shares and GBP 23,000,000 in respect of preference shares) as described in full on pages 11 to 12 of the accompanying Proxy Statement.	Management	For	For
6.	To, subject to the passing of Resolution No. 5, disapply statutory pre-emption rights otherwise applicable to shares in the Company allotted by the Board of Directors, up to an aggregate nominal amount of GBP 148,000,000 (being the aggregate nominal amount of GBP 125,000,000 in respect of ordinary shares and GBP 23,000,000 in respect of preference shares) as described in full on pages 13 to 14 of the accompanying Proxy Statement.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	21-May-2019
Record Date	22-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director: Dr. Brian J. Druker	Management	For	For
1d.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1e.	Election of Director: Mr. Greg C. Garland	Management	For	For
1f.	Election of Director: Mr. Fred Hassan	Management	For	For
1g.	Election of Director: Dr. Rebecca M. Henderson	Management	For	For
1h.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1i.	Election of Director: Dr. Tyler Jacks	Management	For	For
1j.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1k.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1l.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2019.	Management	For	For

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	27-Jun-2019
Record Date	29-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	John F. Crowley		For	For
	2	Margaret G. McGlynn		For	For
	3	Michael G. Raab		For	For
	4	Glenn P. Sblendorio		For	For
2.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool.		Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
4.	Approval, on an advisory basis, the Company’s executive compensation.		Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Dec-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Amended and Restated Certificate of Incorporation; Reverse Stock Split	Management	For	For
2	Approval of Amendment to 2013 Stock Incentive Plan	Management	For	For
3	Approval of Increase in Board Size	Management	For	For
4	Amended and Restated Bylaws	Management	For	For
5	Waiver of Right of First Offer	Management	For	For
6	Omnibus Resolutions	Management	For	For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Dec-2018
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1		Election of Series C Directors		Management		For		For

AMPHIVENA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-May-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Certificate of Amendment to Amended and Restated Certificate of Incorporation	Management	For	For
2	Omnibus Resolutions	Management	For	For

ANAPTYSBIO INC

Security	032724106	Meeting Type	Annual
Ticker Symbol	ANAB	Meeting Date	11-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Hamza Suria		For	For
	2	J. Anthony Ware		For	For
2.	To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	Non-binding advisory vote on compensation of our named executive officers.		Management	For	For
4.	Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation.		Management	1 Year	For

ARCA BIOPHARMA, INC.

Security	00211Y407	Meeting Type	Special
Ticker Symbol	ABIO	Meeting Date	18-Oct-2018
Record Date	12-Sep-2018

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Amendment to the Company’s Certificate of Incorporation to effect a reverse split of the Company’s outstanding common stock, in which from three to twenty shares of common stock would be combined into one share and to authorize the Company’s Board of Directors to select and file one such certificate of amendment within the next.		Management		For		For

ARDELYX, INC

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	13-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Geoffrey A. Block, M.D.		For	For
	2	David Mott		For	For
	3	Michael Raab		For	For
2.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2019.		Management	For	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Annual
Ticker Symbol	ARNA	Meeting Date	13-Jun-2019
Record Date	24-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jayson Dallas, M.D.		For	For
	2	Oliver Fetzer, Ph.D.		For	For
	3	Kieran T. Gallahue		For	For
	4	Jennifer Jarrett		For	For
	5	Amit D. Munshi		For	For
	6	Garry A. Neil, M.D.		For	For
	7	Tina S. Nova, Ph.D.		For	For
	8	Manmeet S. Soni		For	For
	9	Randall E. Woods		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.		Management	For	For
3.	To approve an amendment and restatement of the Arena Pharmaceuticals, Inc. Amended and Restated 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the Amended and Restated 2017 Long-Term Incentive Plan.		Management	For	For
4.	To approve the Arena Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan.		Management	For	For
5.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2019.		Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	07-May-2019
Record Date	08-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
4b.	Adoption of the 2018 annual accounts	Management	For	For
4d.	Allocation of losses of the Company in the financial year 2018 to the retained earnings of the Company	Management	For	For
4e.	Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2018	Management	For	For
5.	Re-appointment of Donald deBethizy as non-executive director to the board of directors of the Company	Management	For	For
6.	Approval of the amended argenx option plan	Management	For	For
7.	Authorization of the board of directors to grant options (rights to subscribe for shares) pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the annual general meeting	Management	Against	Against
8.	Authorization of the board of directors to issue shares in the share capital of the Company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting	Management	Against	Against
9.	Authorization of the board of directors to limit or exclude pre-emptive rights regarding an issuance of new shares or grant rights to subscribe for shares pursuant to the authorization referred to under 7. and 8. above for a period of 18 months from the annual general meeting	Management	Against	Against
10.	Appointment of Deloitte Accountants B.V. as statutory auditor for the 2019 financial year	Management	For	For

ARQULE, INC.

Security	04269E107	Meeting Type	Annual
Ticker Symbol	ARQL	Meeting Date	14-May-2019
Record Date	20-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Susan L. Kelley, M.D.		For	For
	2	Michael D. Loberg Ph.D.		For	For
2.	To approve an amendment to our 2014 Equity Incentives Plan to increase the number of shares of our Common Stock available for issuance pursuant to future awards made under the plan by 2,750,000.		Management	For	For
3.	To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2019.		Management	For	For
4.	To approve, by non-binding vote, the compensation of our named executive officers.		Management	For	For

ARRAY BIOPHARMA INC.

Security	04269X105	Meeting Type	Annual
Ticker Symbol	ARRY	Meeting Date	25-Oct-2018
Record Date	29-Aug-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III director: Charles M. Baum, M.D., Ph.D.	Management	For	For
1b.	Election of Class III director: Gwen Fyfe, M.D.	Management	For	For
2.	Amendment of our Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock from 280,000,000 to 340,000,000.	Management	For	For
3.	Advisory vote to approve the compensation of our named executive officers as disclosed in the accompanying Proxy Statement.	Management	For	For
4.	Ratification of the appointment of KPMG LLP as our independent registered public accountants for the fiscal year ending June 30, 2019.	Management	For	For

ARROWHEAD PHARMACEUTICALS, INC.

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	14-Mar-2019
Record Date	23-Jan-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Christopher Anzalone		For	For
	2	Mauro Ferrari		For	For
	3	Douglass Given		For	For
	4	Michael S. Perry		For	For
	5	William Waddill		For	For
2.	To approve, in an advisory (non-binding) vote, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.		Management	For	For
3.	To recommend, in an advisory (non-binding) vote, the frequency of an advisory vote to approve the compensation paid to the Company’s named executive officers.		Management	1 Year	For
4.	To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2019.		Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Special
Ticker Symbol	ASND	Meeting Date	02-Nov-2018
Record Date	03-Oct-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting: Anders Carstensen	Management	For	For
2.	Election of new Board Member: Lars Holtug	Management	For	For
3.	Authorisation of the Chairman of the Meeting	Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	29-May-2019
Record Date	24-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company’s Activities during the Past Year	Management	For	For
3.	Presentation of Audited Annual Report with Auditor’s Statement for Approval and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5a.	Election of Board Member Class I, with a term expiring at the annual general meeting to be held in 2021: James I. Healy	Management	For	For
5b.	Election of Board Member Class I, with a term expiring at the annual general meeting to be held in 2021: Jan Moller Mikkelsen	Management	For	For
5c.	Election of Board Member Class I, with a term expiring at the annual general meeting to be held in 2021: Lisa Morrison	Management	For	For
5d.	Election of Board Member Class I, with a term expiring at the annual general meeting to be held in 2021: Michael Wolff Jensen	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7A.	The Board of Directors proposes to amend the Articles of Association by renewing the existing authorization in article 4d(1) that authorize to the Board of Directors to increase the company’s share capital at one or more times by up to nominal 9,000,000 with pre-emptive subscription rights for the company’s shareholders.	Management	For	For
7B.	The Board of Directors proposes to amend the Articles of Association by renewing and amending the existing authorization in article 4d(2) that authorize the Board of Directors to increase the company’s share capital at one or more times by up to nominal 9,000,000 without pre-emptive subscription rights for the company’s shareholders.	Management	For	For
7C.	The Board of Directors proposes to amend the Articles of Association by renewing and amending the existing authorization in article 4e that authorize the Board of Directors to issue convertible bonds which gives the right to subscribe for shares in the Company by a nominal value at up to 9,000,000.	Management	For	For

ATHENEX, INC.

Security	04685N103	Meeting Type	Annual
Ticker Symbol	ATNX	Meeting Date	11-Jun-2019
Record Date	15-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kim Campbell		For	For
	2	Manson Fok		For	For
	3	John M. Vierling, M.D.		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Athenex, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

ATRECA, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Jun-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment and Restatement of Certificate of Incorporation Effective Upon Closing of IPO	Management	For	For
2	Amendment and Restatement of Bylaws Effective Upon Closing of IPO	Management	For	For
3	Approval of Form of Indemnity Agreement	Management	For	For
4	Approval of 2019 Equity Incentive Plan	Management	For	For
5	Approval of 2019 Employee Stock Purchase Plan	Management	For	For
6	Additional Filings	Management	For	For
7	General Authorizing Resolution	Management	For	For

ATRECA, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Jun-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Reverse Stock Split	Management	For	For
2	Amendment and Restatement of Certificate of Incorporation to Effect Reverse Stock Split and Authorized Shares Increase	Management	For	For
3	General Authorizing Resolution	Management	For	For

ATRECA, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Jun-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Waiver of Registration Rights	Management	For	For
2	Automatic Conversion of Preferred Stock	Management	For	For

AUDENTES THERAPEUTICS, INC

Security	05070R104	Meeting Type	Annual
Ticker Symbol	BOLD	Meeting Date	07-Jun-2019
Record Date	15-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Scott Morrison		For	For
	2	Matthew Patterson		For	For
	3	Julie Anne Smith		For	For
2.	To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve a non-binding advisory vote on the compensation of our named executive officers.		Management	For	For
4.	To determine by a non-binding advisory vote on whether future non-binding advisory votes on the compensation of our named executive officers should be held every one, two or three years.		Management	1 Year	For

BEIGENE LTD

Security	07725L102	Meeting Type	Special
Ticker Symbol	BGNE	Meeting Date	07-Dec-2018
Record Date	25-Oct-2018

Item	Proposal	Proposed by	Vote	For/Against Management
S1	THAT the adoption of the official Chinese company name for BeiGene, Ltd. be and is hereby approved and adopted. Please see enclosed Company materials for full proposal.	Management	For	For
S2	THAT the Fifth Amended and Restated Memorandum and Articles of Association of the Company be and are hereby approved and adopted.	Management	For	For
O3	THAT the granting of a share issue mandate to the Board of Directors of the Company to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares not exceeding 20% of the total number of issued ordinary shares of the Company as at the date of passing of this ordinary resolution ...(see enclosed Company materials for full proposal).	Management	For	For
O4	THAT the Company and its underwriters be and are hereby authorized, at their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the “Existing Shareholders”), up to a maximum amount of shares in order to ...(see enclosed Company materials for full proposal).	Management	For	For
O5	THAT the BeiGene, Ltd. Second Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved and adopted.	Management	For	For
O6	THAT the BeiGene, Ltd. Second Amended and Restated 2018 Employee Share Purchase Plan be and is hereby approved and adopted.	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	05-Jun-2019
Record Date	18-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Ranjeev Krishana be and is hereby re-elected to serve as a Class III director of the Company until the 2022 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
2.	THAT Xiaodong Wang be and is hereby re-elected to serve as a Class III director of the Company until the 2022 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
3.	THAT Qingqing Yi be and is hereby re-elected to serve as a Class III director of the Company until the 2022 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT Jing-Shyh (Sam) Su be and is hereby re-elected to serve as a Class I director of the Company until the 2020 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
5.	THAT the appointment of Ernst & Young Hua Ming LLP and Ernst & Young as the Company’s independent registered public accounting firms for the year ending December 31, 2019 be and is hereby approved, ratified and confirmed.	Management	For	For
6.	THAT the granting of a share issue mandate to the Board of Directors of the Company to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares not exceeding 20% of the total number of issued ordinary shares of the Company as at the date of passing of this ordinary resolution up to the next annual general meeting of the Company be and is hereby approved.	Management	For	For
7.	THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the “Existing Shareholders”),up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share ...(due to space limits, see proxy material for full proposal).	Management	For	For
8.	THAT, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.	Management	For	For

BELLICUM PHARMACEUTICALS INC

Security	079481107	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	13-Jun-2019
Record Date	17-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	James F. Brown		For	For
	2	Edmund P. Harrigan, MD		For	For
	3	Judith Klimovsky, M.D.		For	For
2.	Approval of the Company’s 2019 Equity Incentive Plan.		Management	For	For
3.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.		Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Sep-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Director Election	Management	For	For
2	General Authorizing Resolution	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	4-Sep-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Director Removal	Management	For	For
2	General Authorizing Resolution	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	1-Nov-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment of Certificate of Incorporation	Management	For	For
2	Amendment and Restatement of 2013 Stock Option and Grant Plan	Management	For	For
3	General Authorizing Resolution	Management	For	For

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	19-Jun-2019
Record Date	22-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: John R. Chiminski	Management	For	For
1b.	Election of Director: Alexander J. Denner	Management	For	For
1c.	Election of Director: Caroline D. Dorsa	Management	For	For
1d.	Election of Director: William A. Hawkins	Management	For	For
1e.	Election of Director: Nancy L. Leaming	Management	For	For
1f.	Election of Director: Jesus B. Mantas	Management	For	For
1g.	Election of Director: Richard C. Mulligan	Management	For	For
1h.	Election of Director: Robert W. Pangia	Management	For	For
1i.	Election of Director: Stelios Papadopoulos	Management	For	For
1j.	Election of Director: Brian S. Posner	Management	For	For
1k.	Election of Director: Eric K. Rowinsky	Management	For	For
1l.	Election of Director: Lynn Schenk	Management	For	For
1m.	Election of Director: Stephen A. Sherwin	Management	For	For
1n.	Election of Director: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For

BIOMARIN PHARMACEUTICAL INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	04-Jun-2019
Record Date	08-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jean-Jacques Bienaimé		For	For
	2	Willard Dere		For	For
	3	Michael Grey		For	For
	4	Elaine J. Heron		For	For
	5	Robert J. Hombach		For	For
	6	V. Bryan Lawlis		For	For
	7	Alan J. Lewis		For	For
	8	Richard A. Meier		For	For
	9	David E.I. Pyott		For	For
	10	Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.		Management	For	For
4.	To approve an amendment to the 2017 Equity Incentive Plan.		Management	For	For
5.	To approve amendments to the Amended and Restated 2006 Employee Stock Purchase Plan.		Management	For	For

BLUEBIRD BIO, INC.

Security	09609G100	Meeting Type	Annual
Ticker Symbol	BLUE	Meeting Date	06-Jun-2019
Record Date	15-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Wendy L. Dixon, Ph.D.	Management	For	For
1b.	Election of Class III Director: David P. Schenkein, M.D.	Management	For	For
2.	To hold a non-binding advisory vote on the compensation paid to the Company’s named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	18-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey W. Albers		For	For
	2	Mark Goldberg, M.D.		For	For
	3	Nicholas Lydon, Ph.D.		For	For
2.	To approve an advisory vote on named executive officer compensation.		Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2019.		Management	For	For

CELLECTIS S.A.

Security	15117K103	Meeting Type	Annual
Ticker Symbol	CLLS	Meeting Date	25-Jun-2019
Record Date	10-Jun-2019

Item	Proposal	Proposed by	Vote	For/Against Management
O1	Approval of the financial statements for the financial year ended December 31, 2018	Management	For	For
O2	Approval of the consolidated financial statements for the financial year ended December 31, 2018	Management	For	For
O3	Allocation of income for the financial year ended December 31, 2018	Management	For	For
O4	Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code	Management	For	For
O5	Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code	Management	For	For
O6	Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code	Management	For	For
O7	Approval of 2018 Stock Option Plan and payment for the stock (Due to space limits, see proxy material for full proposal)	Management	For	For
O8	Authorization to be given to the board of directors to buy back Company shares	Management	For	For
E9	Authorization to be given to the board of directors for the (Due to space limits, see proxy material for full proposal)	Management	For	For
E10	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E11	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E12	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E13	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E14	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E15	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E16	Delegation granted to the board of directors to increase the (Due to space limits, see proxy material for full proposal)	Management	For	For
E17	Overall limitations to the amount of issuances made under the (Due to space limits, see proxy material for full proposal)	Management	For	For
E18	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E19	Authorization to be given to the board of directors to grant options to subscribe or purchase Company’s shares	Management	For	For
E20	Authorization be given to the board of directors for the (Due to space limits, see proxy material for full proposal)	Management	For	For
E21	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E22	Delegation of authority to be granted to the board of directors (Due to space limits, see proxy material for full proposal)	Management	For	For
E23	Authorization for the board of directors to freely allocate (Due to space limits, see proxy material for full proposal)	Management	For	For
E24	Overall limitations to the amount of issues made under the 19th (Due to space limits, see proxy material for full proposal)	Management	For	For
E25	Delegation to be granted to the board of directors for the (Due to space limits, see proxy material for full proposal)	Management	For

CIDARA THERAPEUTICS, INC.

Security	171757107	Meeting Type	Annual
Ticker Symbol	CDTX	Meeting Date	17-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey Stein		For	For
	2	David Gollaher		For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors to serve as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2019.		Management	For	For

CLEARSIDE BIOMEDICAL, INC.

Security	185063104	Meeting Type	Annual
Ticker Symbol	CLSD	Meeting Date	20-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	G Lasezkay, Pharm.D, JD		For	For
	2	Christy L Shaffer, Ph.D		For	For
2.	RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2019.		Management	For	For

CLOVIS ONCOLOGY, INC.

Security	189464100	Meeting Type	Annual
Ticker Symbol	CLVS	Meeting Date	06-Jun-2019
Record Date	08-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Brian G. Atwood		For	For
	2	James C. Blair, Ph.D.		For	For
	3	Richard A. Fair		For	For
	4	Paul H. Klingenstein		For	For
2.	Amendment to our Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock from 100,000,000 to 200,000,000.		Management	For	For
3.	Approval of an advisory proposal on compensation of the Company’s named executive officers, as disclosed in the attached proxy statement.		Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2019.		Management	For	For

COHERUS BIOSCIENCES INC

Security	19249H103	Meeting Type	Annual
Ticker Symbol	CHRS	Meeting Date	22-May-2019
Record Date	29-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Samuel Nussbaum, M.D.		For	For
	2	Mary T. Szela		For	For
	3	Ali J. Satvat		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

CONCERT PHARMACEUTICALS, INC.

Security	206022105	Meeting Type	Annual
Ticker Symbol	CNCE	Meeting Date	13-Jun-2019
Record Date	16-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of class II director to our Board of Directors to serve until the 2022 annual meeting of stockholders: Ronald W. Barrett	Management	For	For
1b.	Election of class II director to our Board of Directors to serve until the 2022 annual meeting of stockholders: Jesper Høiland	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

CRISPR THERAPEUTICS AG

Security	H17182108	Meeting Type	Annual
Ticker Symbol	CRSP	Meeting Date	11-Jun-2019
Record Date	12-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2018.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman)	Management	For	For
4b.	Re-election of the member to the Board of Director:	Management	For	For
	Samarth Kulkarni, Ph.D.
4c.	Re-election of the member to the Board of Director: Ali Behbahani, M.D.	Management	For	For
4d.	Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D.	Management	For	For
4e.	Re-election of the member to the Board of Director: Pablo Cagnoni, M.D.	Management	For	For
4f.	Re-election of the member to the Board of Director: Simeon J. George, M.D.	Management	For	For
4g.	Election of the member to the Board of Director: John T. Greene	Management	For	For
4h.	Election of the member to the Board of Director: Katherine A. High, M.D.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D.	Management	For	For
5c.	Election of the member of the Compensation Committee: John T. Greene	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2019 Annual General Meeting to the 2020 Annual General Meeting of Shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2019 Annual General Meeting to the 2020 Annual General Meeting of Shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2019 to June 30, 2020.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2019.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2019 Annual General Meeting to the 2020 Annual General Meeting of Shareholders.	Management	For	For
7.	Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers under U.S. securities law requirements.	Management	For	For
8.	Non-binding advisory vote on the frequency of future shareholder advisory votes on the compensation paid to the Company’s named executive officers under U.S. securities law requirements.	Management	1 Year	Against
9.	The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.	Management	For	For
10.	The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.	Management	For	For
11.	The approval of amending and restating art. 3a of the Articles of Association.	Management	For	For
12.	The approval of amending and restating art. 4 of the Articles of Association.	Management	For	For
13.	The approval of amending and restating art. 16 of the Articles of Association.	Management	For	For
14.	The approval of amending and restating art. 17 of the Articles of Association.	Management	For	For
15.	The approval of amending and restating art. 41 of the Articles of Association.	Management	For	For
16.	The re-election of the independent voting rights representative.	Management	For	For
17.	The election of the auditors.	Management	For	For

CURASEN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	15-Mar-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Waiver of Audited Financial Statements	Management	For	For
2	General Authority and Ratification	Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-Jan-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment of Amended and Restated Certificate of Incorporation	Management	For	For
2	Approval of 2019 Bridge Financing	Management	For	For
3	General Authorizing Resolution	Management	For	For

DECIPHER BIOSCIENCES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Mar-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment and Restatement of Certificate of Incorporation	Management	For	For
2	Series 3 Preferred Stock Financing	Management	For	For
3	Amendment of 2018 Equity Incentive Plan	Management	For	For
4	General Authorizing Resolution	Management	For	For

DENALI THERAPEUTICS INC.

Security	24823R105	Meeting Type	Annual
Ticker Symbol	DNLI	Meeting Date	30-May-2019
Record Date	11-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Peter Klein		For	For
	2	Robert Nelsen		For	For
	3	Vicki Sato, Ph.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019.		Management	For	For

EDITAS MEDICINE INC

Security	28106W103	Meeting Type	Annual
Ticker Symbol	EDIT	Meeting Date	12-Jun-2019
Record Date	16-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jessica Hopfield, Ph.D.		For	For
	2	David T. Scadden, M.D.		For	For
2.	To approve, on an advisory basis, named executive officer compensation.		Management	For	For
3.	To approve, on an advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers.		Management	1 Year	For
4.	To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

ENDO INTERNATIONAL PLC

Security	G30401106	Meeting Type	Annual
Ticker Symbol	ENDP	Meeting Date	11-Jun-2019
Record Date	12-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Roger H. Kimmel	Management	For	For
1b.	Election of Director: Paul V. Campanelli	Management	For	For
1c.	Election of Director: Shane M. Cooke	Management	For	For
1d.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1e.	Election of Director: Michael Hyatt	Management	For	For
1f.	Election of Director: Sharad S. Mansukani, M.D.	Management	For	For
1g.	Election of Director: William P. Montague	Management	For	For
2.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
3.	To approve the Endo International plc Amended and	Management	For	For
	Restated 2015 Stock Incentive Plan.
4.	To renew the Board’s existing authority to issue shares under Irish law.	Management	For	For
5.	To renew the Board’s existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For
6.	To approve the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2019 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm’s remuneration.	Management	For	For

ENDOCYTE INC

Security	29269A102	Meeting Type	Special
Ticker Symbol	ECYT	Meeting Date	20-Dec-2018
Record Date	15-Nov-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To adopt the Agreement and Plan of Merger, dated as of October 17, 2018 (as it may be amended from time to time, the “merger agreement”), by and among Novartis AG, Edinburgh Merger Corporation (“Merger Sub”) and Endocyte, Inc., pursuant to which Merger Sub will be merged with and into Endocyte, Inc., with Endocyte, Inc. continuing as a wholly owned subsidiary of Novartis AG (the “merger”).	Management	For	For
2.	To approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Endocyte Inc.’s named executive officers in connection with the merger.	Management	For	For
3.	To approve the adjournment of the special meeting, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve the proposal to adopt the merger agreement.	Management	For	For

EPIZYME, INC.

Security	29428V104	Meeting Type	Annual
Ticker Symbol	EPZM	Meeting Date	31-May-2019
Record Date	05-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael F. Giordano, MD		For	For
	2	David M. Mott		For	For
	3	Richard F. Pops		For	For
2.	Ratification of the Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2019.		Management	For	For
3.	Advisory Vote on Executive Compensation.		Management	For	For
4.	Advisory Vote on the Frequency of Future Executive Compensation Advisory Votes.		Management	1 Year	For

ESPERION THERAPEUTICS INC

Security	29664W105	Meeting Type	Annual
Ticker Symbol	ESPR	Meeting Date	29-May-2019
Record Date	01-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class III Director: Scott Braunstein, M.D.	Management	For	For
1b.	Election of Class III Director: Jay P. Shepard	Management	For	For
2.	To approve the advisory resolution on the compensation of our named executive officers	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019	Management	For	For

EXELIXIS, INC.

Security	30161Q104	Meeting Type	Annual
Ticker Symbol	EXEL	Meeting Date	22-May-2019
Record Date	25-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class II Director to hold office until the 2022 Annual Meeting of stockholder: Carl B. Feldbaum, Esq.	Management	For	For
1.2	Election of Class II Director to hold office until the 2022 Annual Meeting of stockholder: Maria C. Freire, Ph.D.	Management	For	For
1.3	Election of Class II Director to hold office until the 2022 Annual Meeting of stockholder: Alan M. Garber, M.D., Ph.D.	Management	For	For
1.4	Election of Class II Director to hold office until the 2022 Annual Meeting of stockholder: Vincent T. Marchesi, M.D., Ph.D.	Management	For	For
1.5	Election of Class II Director to hold office until the 2022 Annual Meeting of stockholder: Julie Anne Smith	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending January 3, 2020.	Management	For	For
3.	To approve the proposal of Exelixis’ Board of Directors to amend Exelixis’ Amended and Restated Certificate of Incorporation to declassify the Board of Directors to provide for annual elections by the 2020 Annual Meeting of Stockholders.	Management	For	For
4.	To approve, on an advisory basis, the compensation of Exelixis’ named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

FIBROGEN, INC.

Security	31572Q808	Meeting Type	Annual
Ticker Symbol	FGEN	Meeting Date	05-Jun-2019
Record Date	09-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Jeffrey L. Edwards	Management	For	For
1b.	Election of Class II Director: Rory B. Riggs	Management	For	For
1c.	Election of Class II Director: Roberto Pedro Rosenkranz, Ph.D., M.B.A.	Management	For	For
2.	To approve, on an advisory basis, the compensation of FibroGen’s named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2019.	Management	For	For

FOAMIX PHARMACEUTICALS LTD

Security	M46135105	Meeting Type	Annual
Ticker Symbol	FOMX	Meeting Date	10-Apr-2019
Record Date	28-Feb-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1	Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services.	Management	For	For
2a	Ratify the election of Mr. Anthony Bruno as a director of the Company.	Management	For	For
2b	Ratify the election of Ms. Sharon Barbari as a director of the Company.	Management	For	For
3a	Approve certain retirement payment and benefits for Dr. Darrell Rigel, as set out in subclause (a) of Proposal 3 of the Company’s proxy statement.	Management	For	For
3a1	For purposes of Proposal 3(a) please confirm that you are NOT a “controlling shareholder” and that you do NOT have a “personal interest” in the approval of Proposal 3(a), as such terms are defined in the Israeli Companies Law. (Note: If you do not mark the ‘FOR’ box, it will be deemed that you are a controlling shareholder and that you do have a personal interest and your vote will not be counted).	Management	For
3b	Approve certain retirement payment and benefits for Dr. Dalia Megiddo, as set out in sub-clause (b) of Proposal 3 of the Company’s proxy statement.	Management	For	For
3b1	For purposes of Proposal 3(b) please confirm that you are NOT a “controlling shareholder” and that you do NOT have a “personal interest” in the approval of Proposal 3(b), as such terms are defined in the Israeli Companies Law. (Note: If you do not mark the ‘FOR’ box, it will be deemed that you are a controlling shareholder and that you do have a personal interest and your vote will not be counted).	Management	For
4	Approve the Company’s 2019 Equity Incentive Plan.	Management	For	For
5	Approve the Company’s 2019 Employee Stock Purchase Plan.	Management	For	For
6a	Approve an increase in Mr. Domzalski’s annual base salary to $560,000, effective January 1, 2019, as set out under sub- clause (a) of Proposal 6 in the Company’s proxy statement.	Management	For	For
6a1	For purposes of Proposal 6(a) please confirm that you are NOT a “controlling shareholder” and that you do NOT have a “personal interest” in the approval of Proposal 6(a), as such terms are defined in the Israeli Companies Law. (Note: If you do not mark the ‘FOR’ box, it will be deemed that you are a controlling shareholder and that you do have a personal interest and your vote will not be counted).	Management	For
6b	Approve the terms of Mr. Domzalski’s cash bonus and equity compensation for 2019, as set out under sub- clause (b) of Proposal 6 of the Company’s proxy statement.	Management	For	For
6b1	For purposes of Proposal 6(b) please confirm that you are NOT a “controlling shareholder” and that you do NOT have a “personal interest” in the approval of Proposal 6(b), as such terms are defined in the Israeli Companies Law. (Note: If you do not mark the ‘FOR’ box, it will be deemed that you are a controlling shareholder and that you do have a personal interest and your vote will not be counted).	Management	For
6c	Approve Mr. Domzalski’s eligibility to participate in the Company’s 2019 Employee Stock Purchase Plan, if approved, as set out under sub-clause (c) of Proposal 6 of the Company’s proxy statement.	Management	For	For
6c1	For purposes of Proposal 6(b) please confirm that you are NOT a “controlling shareholder” and that you do NOT have a “personal interest” in the approval of Proposal 6(b), as such terms are defined in the Israeli Companies Law. (Note: If you do not mark the ‘FOR’ box, it will be deemed that you are a controlling shareholder and that you do have a personal interest and your vote will not be counted).	Management	For
7	Approve an increase of the authorized share capital of the Company from 90,000,000 to 135,000,000 ordinary shares with a nominal value of NIS 0.16 per share and a corresponding amendment to the Articles of Association of the Company.	Management	For	For

GALAPAGOS N V

Security	36315X101	Meeting Type	Annual
Ticker Symbol	GLPG	Meeting Date	30-Apr-2019
Record Date	22-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
O2	Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2018 and approval of the allocation of the annual result as proposed by the board of directors.	Management	For	For
O5	Acknowledgement and approval of the remuneration report.	Management	For	For
O6	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2018.	Management	For	For
O7	Revision of the remuneration of the statutory auditor.	Management	For	For
O8	Appointment of Mr. Peter Guenter as director of the Company.	Management	For	For
O9	Remuneration of directors.	Management	For	For
O10	Offer of warrants.	Management	For	For
S11	Application of article 556 of the Belgian Companies Code.	Management	For	For

GALAPAGOS NV

Security	B44170106	Meeting Type	Annual General Meeting
Ticker Symbol	GLPGF	Meeting Date	30-Apr-2019
Record Date	16-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1	Acknowledgement and Discussion of the Annual Report of Directors Relating to the Non-Consolidated and Consolidated Annual Accounts of the Company for the Financial Year Ended 31 December 2018, and of the Report of the Statutory Auditor Relating to the Non-Consolidated Annual Accounts of the Company for the Financial Year Ended on 31 December 2018.	Non-Voting
2	Acknowledgement and Approval of the Non-Consolidated Annual Accounts of the Company for the Financial Year Edned on 31 December 2018 and Approval of the Allocation of the Annual Result as Proposed by the Board of Directors.	Management	For	For
3	Acknowledgement and Discussion of the Report of the Statutory Auditor Relating to the Consolidated Annual Accounts of the Company for the Financial Year Ended on 31 December 2018.	Non-Voting
4	Acknowledgement and Discussion of the Consolidated Annual Accounts of the Company for the Financial Year Ended on 31 December 2018.	Non-Voting
5	Acknowledge and Approval of the Remuneration Report	Management	For	For
6	Release from Liability to be Granted to the Directors and the Statutory Auditor for the Performance of their Duties in the Course of the Financial Year Ended 31 December 2018.	Management	For	For
7	Revision of the Rumeration of the Statutory Auditor: the Shareholders’ Meeting Resolves to Increase the Annual Remuneration of the Statutory Auditor from EUR 350,000 to (I) EUR 430,000 for its Activities Relating to the Statutory Annual Accounts, the Consolidated Annual Accounts and the Interim Reporting of the Company and its Subsidiaries for the Financial Year Ended 31 December 2018 and (II) EUR 630,000 for its Activities Relating to the Statutory Annual Accounts, the Consolidated Annual Accounts and the Interim Reporting of the Company and its Subsidiaries for the Financial Year Ending 31 December 2018.	Management	For	For
8	Appointment of a Director: The Shareholders’ Meeting Resolves to Appoint Mr. Peter Guenter (Residing in Barcelona, Spain) as Director of the Company, for a Period of Four Years Ending Immediately After the Annual Shareholders’ Meeting to be Held in 2023 and, Upon the Proposal of the Board of Directors and in Accordance with the Advice of the Company’s Nomination and Remuneration Committee, to Appoint Mr. Peter Guenter as an Independent Director as He Meets the Independence Criteria Set Forth in Article 526TER of the Belgian Companies Code.	Management	For	For
9	Remuneration of Directors: Upon Recommendation of the Company’s Nomination and Remuneration Committee, the Shareholders’ Meeting Resolves That (A) the Compensation (Excluding Expenses) of the Non-Executive Directors for the Exercise of Their Mandate is Established as Follows: (I) Chairman of the Board: EUR 80,000 Per Annum; (II) Other Non-Executive Board Members: EUR 40,000 Each Per Annum;	Management	For	For

	(III) Additional Compensation for Membership of a Board Committee: EUR 5,000 Per Annum; (IV) Additional Compensation for the Chairmanship of a Board Committee: EUR 10,000 Per Annum; and (B) A Power of Attorney is Granted to the Board of Directors to Determine the Total Remuneration Package of the Managing Director (CEO) for his Management Function in the Company, It Being Understood That This Remuneration Shall Include a Compensation for the Performance of his Mandate as a Director of the Company.
10	Offer of Warrants: Upon Recommendation of the Company’s Remuneration Committee, The Shareholders’ Meeting (I) Resolves to Offer 100,000 Warrants to Mr. Onno Van De Stolpe, 15, 0000 Warrants to Dr. Raj Parekh, and 7,500 Warrants Each to of Mr. Howard Rowe, Ms. Katrine Bosley, Dr. Mary Kerr and Mr. Peter Guenter, Under Warrant Plans Created (Or To Be Created) by the Board of Directors for the Benefit of Directors, Employees, and Independent Consultants of Galapagos and its Affiliates Within the Framework of the Authorized Capital (Jointly “Warrant Plan 2019”), the Key Conditions of Which Will Be In Line with Previous Warrant Plans of the Company, (II) Empowers the Managing Director, as well as Any Other Director as Regards the Offer to the Managing Director, to Implement this Offer, and (III) to the Extent Required, Approves the Offer of Warrants to Members of Galapagos’ Executive Committee under Warrant Plan 2019 in Accordance with Galapagos’ Remuneration Policy and Practices. In Accordance with Articles 520TER and 556 of the Belgian Companies Code, the Shareholders’ Meeting Expressly Approves the Particular Provisions that will be included in Warrant Plan 2019 pursuant to which, in Exceptional Circumstances (Including in the Event of a Change in Control of the Company), the Warrants Offered (to the Extent Accepted) Under Warrant Plan 2019 Can Be Exercised Early, Even Before the Third Anniversary of Their Award.	Management	For	For
11	Application of Article 556 of the Belgian Companies Code: Proposed Resolution: In Accordance with Article 556 of the Belgian Companies Code, the Shareholders’ Meeting Resolves to Approve, And to the Extent Required, Ratify All of the Provisions Granting Rights to Third Parties Which Could Affect the Assets of the Company, Or Could Impose an Obligation on the Company, where the Exercise of Those Rights is Depedent on a Public Takeover Bid on the Shares of the Company or a Change of Control in Respect of the Company, as Included in: (A) The Second Amended and Restated Collaboration Agreement Between Galapagos NV and Abbvie S.A.R.L. Dated 24 October 2018 (The “Abbvie Agreement”) Including, But Not Limited To, Clause 11.2 (Change in Control of Galapagos) of the Abbvie Agreement, Entitling the Counterparty, in the Event of A Change in Control of the Company, to Oblige the Company to Take Appropriate Measures to Avoid the Disclosure of Confidential Information, to Limit Abbvie’s Reporting Obligations to the Company, or, Depending on the Stage in Which the Change of Control Occurs, to Terminate the Abbvie Agreement; (B) The Exclusive License Agreement Among Galapagos NV, Morphosys AG and Novartis Pharma AG Dated 19 July 2019 (the “Novartis Agreement”), Including, But Not Limited To, Clause 3.7 of the Novartis Agreement (Change of Control), Entitling	Management	For	For

		Novartis, in the Event of a Change of Control of the Company, to Have The Company’s Representatives Removed from the Joint Committees; And (C) the Product Development, License And Commercialization Agreement Between Galapagos NV, Les Laboratoires Servier and Institut de Recherches Servier as Amended and Restated 8 May 2018 (The “Servier Agreement”), Including But Not Limited To Clause 13.4 (Termination by Servier Without Cause or Due to Galapagos Change of Control), Clause 13.5 (Rights on Termination) and Clause 13.7 (Change of Control), Entitling the Counterparty, In the Event of a Change of Control of the Company, To Elect to Terminate the Servier Agreement Subject to an Option for the Company to Choose from Two Contractual Termination Regimes, Both Including The Termination of the Licenses Granted by the Company to Servier and the Freedom for the Company to Conduct Research and Development Activities on Terminated Licensed Products, or to Have The Licenses Granted to Servier Continue, With All Payment Obligations Remaining in Place, but with Servier Having Full Control Over the Further Development and Patent Strategies for the Licensed Product in Servier’s Territory. The Shareholders’ Meeting Grants a Special Power of Attorney to Each Director of the Company, as well as to Mr. Xavier Maes, Ms. Ellen Lefever, Ms. Anneslies Denecker, and Ms. Lauran Diependaele, Each Acting Individually and with the Power of Substitution, to File this Resolution with the Clerk’s Office of the Commercial Court of Antwerp, Division of Mechelen, in Accordance with Article 556 of the Belgian Companies Code.
12		Miscellaneous		Non-Voting

GALERA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	18-Sep-2018
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1		Royalty Interest Financing		Management		For		For

GALARA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	6-Nov-2018
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1		Amendment to Royalty Interest Agreement		Management		For		For

GALARA THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	22-Mar-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Election of Kevin Loaky to the Board of Directors	Management	For	For
2	General Enabling Resolutions	Management	For	For

GENOMEDX BIOSCIENCES INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	20-Jul-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment and Restatement of Certification of Incorporation	Management	For	For
2	Second Series E Preferred Stock Financing	Management	For	For
3	Approval of 2018 Equity Incentive Plan	Management	For	For
4	General Authorizing Resolution	Management	For	For

GENOMEDX BIOSCIENCES INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	3-Oct-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment and Restatement of Certification of Incorporation	Management	For	For
2	Second Series E Preferred Stock Financing	Management	For	For
3	Board Composition	Management	For	For
4	General Authorizing Resolution	Management	For	For

GENOMEDX BIOSCIENCES INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-Nov-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Amendment and Restatement of Certificate of Incorporation	Management	For	For
2	General Authorization	Management	For	For

GENOMEDX BIOSCIENCES INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-Dec-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Note Financing	Management	For	For
2	General Authorizing Resolution	Management	For	For

GENOMIC HEALTH, INC.

Security	37244C101	Meeting Type	Annual
Ticker Symbol	GHDX	Meeting Date	13-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kimberly J. Popovits		For	For
	2	Felix J. Baker, Ph.D.		For	For
	3	Julian C. Baker		For	For
	4	Fred E. Cohen, M.D.		For	For
	5	B.P. Flannelly, Pharm.D		For	For
	6	Henry J. Fuchs, M.D.		For	For
	7	Ginger L. Graham		For	For
	8	Geoffrey M. Parker		For	For
2.	To vote on the approval of our Amended and Restated 2005 Stock Incentive Plan that includes an increase in the number of shares available for issuance under the plan by 500,000 shares, a change in the automatic equity grants to outside directors, and the addition of certain other best practice plan provisions.		Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.		Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2019.		Management	For	For
5.	To approve a stockholder proposal concerning simple majority voting, if properly presented at the Annual Meeting.		shareholder	Against	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	08-May-2019
Record Date	15-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1b.	Election of Director: John F. Cogan, Ph.D.	Management	For	For
1c.	Election of Director: Kelly A. Kramer	Management	For	For
1d.	Election of Director: Kevin E. Lofton	Management	For	For
1e.	Election of Director: Harish M. Manwani	Management	For	For
1f.	Election of Director: Daniel P. O’Day	Management	For	For
1g.	Election of Director: Richard J. Whitley, M.D.	Management	For	For
1h.	Election of Director: Gayle E. Wilson	Management	For	For
1i.	Election of Director: Per Wold-Olsen	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2019.	Management	For	For
3.	To approve an amendment to Gilead’s Restated Certificate of Incorporation to allow stockholders to act by written consent.	Management	For	For
4.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.	Shareholder	For	Against
6.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board issue a report describing how Gilead plans to allocate tax savings as a result of the Tax Cuts and Jobs Act.	Shareholder	Against	For

GLOBAL BLOOD THERAPEUTICS, INC.

Security	37890U108	Meeting Type	Annual
Ticker Symbol	GBT	Meeting Date	18-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Ted Love, M.D.		For	For
	2	Glenn Pierce, M.D Ph.D.		For	For
	3	Dawn Svoronos		For	For
2.	Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement.		Management	For	For
3.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.		Management	For	For

GW PHARMACEUTICALS PLC

Security	36197T103	Meeting Type	Annual
Ticker Symbol	GWPH	Meeting Date	13-Jun-2019
Record Date	16-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect James Noble as a Director	Management	For	For
O2	To re-elect Thomas Lynch as a Director	Management	For	For
O3	To approve the Directors’ Remuneration Report	Management	For	For
O4	To approve the compensation of the Company’s named executive officers	Management	For	For
O5	To approve the Directors’ Remuneration Policy	Management	For	For
O6	To determine the frequency for approval of the compensation of the Company’s named executive officers	Management	1 Year	For
O7	To ratify the appointment of Deloitte and Touche LLP as the Company’s US public accounting firm	Management	For	For
O8	To re-appoint Deloitte LLP as the UK Auditor	Management	For	For
O9	To authorise the Audit Committee to determine the Auditors’ remuneration	Management	For	For
O10	To receive, consider and adopt the Directors’ and Auditors’ Reports and Statement of Accounts for the 15- month period ended 31 December 2018 and note that the Directors do not recommend the payment of a dividend	Management	For	For
O11	To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the “2006 Act”) such authority to be valid up to 13 June 2020	Management	For	For
S12	Subject to the passing of Resolution 11, to authorise the Directors to allot equity securities, under Section 570 of the 2006 Act as if Section 561(1) of the 2006 Act did not apply to such allotment	Management	For	For

HORIZON PHARMA PLC

Security	G4617B105	Meeting Type	Annual
Ticker Symbol	HZNP	Meeting Date	02-May-2019
Record Date	13-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Michael Grey	Management	For	For
1b.	Election of Class II Director: Jeff Himawan, Ph.D.	Management	For	For
2.	Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019 and authorization of the Audit Committee to determine the auditors’ remuneration.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.	Management	For	For
4.	Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.	Management	For	For
5.	Approval of an increase in the authorized share capital of the Company from Euro40,000 and $30,000 to Euro40,000 and $60,000 by the creation of an additional 300,000,000 ordinary shares of nominal value $0.0001 per share.	Management	For	For
6.	Renewal of the Board of Directors’ existing authority to allot and issue ordinary shares for cash and non-cash consideration under Irish law.	Management	For	For
7.	Renewal of the Board of Directors’ existing authority to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply under Irish law.	Management	For	For
8.	Approval of motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 7.	Management	For	For
9.	Approval of a change of name of our Company to Horizon Therapeutics Public Limited Company.	Management	For	For
10.	Approval of the Amended and Restated 2014 Equity Incentive Plan.	Management	For	For
11.	Approval of the Amended and Restated 2014 Non- Employee Equity Plan.	Management	For	For

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	08-May-2019
Record Date	15-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jonathan W. Ayers	Management	For	For
1b.	Election of Director: Stuart M. Essig, PhD	Management	For	For
1c.	Election of Director: M. Anne Szostak	Management	For	For
2.	Ratification of Appointment of Independent Registered	Management	For	For
	Public Accounting Firm. To ratify the selection of
	PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year.
3.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company’s executive compensation.	Management	For	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Annual
Ticker Symbol	ILMN	Meeting Date	29-May-2019
Record Date	01-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Frances Arnold, Ph.D.	Management	For	For
1B.	Election of Director: Francis A. deSouza	Management	For	For
1C.	Election of Director: Susan E. Siegel	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 29, 2019.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors.	Management	For	For
5.	To approve, on an advisory basis, a stockholder proposal to enhance election-related disclosures.	Shareholder	Against	For

ILLUMINOSS MEDICAL, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Mar-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Equity Incentive Plan	Management	For	For
2	Anti-Dilution	Management	For	For
3	General Resolutions	Management	For	For

IMMUNOGEN, INC.

Security	45253H101	Meeting Type	Annual
Ticker Symbol	IMGN	Meeting Date	20-Jun-2019
Record Date	23-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	To fix the number of members of the Board of Directors at seven (7).		Management	For	For
2	DIRECTOR		Management
	1	Stephen C. McCluski		For	For
	2	Richard J. Wallace		For	For
	3	Mark Goldberg, MD		For	For
	4	Dean J. Mitchell		For	For
	5	Kristine Peterson		For	For
	6	Mark J. Enyedy		For	For
	7	Stuart A. Arbuckle		For	For
3.	To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in our proxy statement.		Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019.		Management	For	For

IMMUNOMEDICS, INC.

Security	452907108	Meeting Type	Annual
Ticker Symbol	IMMU	Meeting Date	07-Jun-2019
Record Date	22-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Behzad Aghazadeh	Management	For	For
1.2	Election of Director: Charles Baum	Management	For	For
1.3	Election of Director: Scott Canute	Management	For	For
1.4	Election of Director: Barbara G. Duncan	Management	For	For
1.5	Election of Director: Peter Barton Hutt	Management	For	For
1.6	Election of Director: Khalid Islam	Management	For	For
2.	Advisory vote to approve the compensation of our named executive officers.	Management	For	For
3.	Proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2019.	Management	For	For

INCYTE CORPORATION

Security	45337C102	Meeting Type	Annual
Ticker Symbol	INCY	Meeting Date	26-Apr-2019
Record Date	12-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaimé	Management	For	For
1.3	Election of Director: Paul A. Brooke	Management	For	For
1.4	Election of Director: Paul J. Clancy	Management	For	For
1.5	Election of Director: Wendy L. Dixon	Management	For	For
1.6	Election of Director: Jacqualyn A. Fouse	Management	For	For
1.7	Election of Director: Paul A. Friedman	Management	For	For
1.8	Election of Director: Hervé Hoppenot	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.	Management	For	For
3.	To approve amendments to the Company’s Amended and Restated 2010 Stock Incentive Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2019.	Management	For	For
5.	To vote on a stockholder proposal, if properly presented, described in more detail in the proxy statement.	Shareholder	For	Against

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	21-May-2019
Record Date	01-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Caroline Dorsa		For	For
	2	Perry Karsen		For	For
	3	John Leonard, M.D.		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	Approve, on an advisory basis, the compensation of the named executive officers.		Management	For	For
4.	Advisory vote on the frequency of advisory votes on executive compensation.		Management	1 Year	For

INTERCEPT PHARMACEUTICALS, INC.

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	20-Jun-2019
Record Date	23-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1)	DIRECTOR		Management
	1	Paolo Fundarò		For	For
	2	Mark Pruzanski, M.D.		For	For
	3	Srinivas Akkaraju		For	For
	4	Luca Benatti, Ph.D.		For	For
	5	Daniel Bradbury		For	For
	6	Keith Gottesdiener, M.D		For	For
	7	Nancy Miller-Rich		For	For
	8	Gino Santini		For	For
	9	Glenn Sblendorio		For	For
	10	Daniel Welch		For	For
2)	To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.		Management	For	For
3)	To ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2019.		Management	For	For

INTRA-CELLULAR THERAPIES INC

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	25-Jun-2019
Record Date	29-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Sharon Mates, Ph.D.		For	For
	2	Rory B. Riggs		For	For
	3	Robert L. Van Nostrand		For	For
2.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in the proxy statement.		Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	06-Jun-2019
Record Date	08-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Stanley T. Crooke		For	For
	2	Joseph Klein, III		For	For
	3	Joseph Loscalzo		For	For
	4	Michael Hayden		For	For
2.	To ratify the appointment of Peter N. Reikes to the Board for a term expiring in 2021.		Management	For	For
3.	To ratify the appointment of Brett Monia to the Board for a term expiring in 2021.		Management	For	For
4.	To approve an amendment and restatement of the lonis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance by 7,000,000 to an aggregate of 23,000,000 shares.		Management	For	For
5.	To approve, by non-binding vote, executive compensation.		Management	For	For
6.	Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2019 fiscal year.		Management	For	For

IOVANCE BIOTHERAPEUTICS, INC.

Security	462260100	Meeting Type	Annual
Ticker Symbol	IOVA	Meeting Date	10-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Iain Dukes, D. Phil		For	For
	2	Maria Fardis, Ph.D.		For	For
	3	Ryan Maynard		For	For
	4	Merrill A. McPeak		For	For
	5	Wayne P. Rothbaum		For	For
	6	Michael Weiser, MD, PhD		For	For
2.	To approve, by non-binding advisory vote, the compensation of our named executive officers.		Management	For	For
3.	To approve an amendment to our Certificate of Incorporation to increase authorized shares of common stock from 150,000,000 to 300,000,000.		Management	For	For
4.	To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019.		Management	For	For

JOUNCE THERAPEUTICS, INC.

Security	481116101	Meeting Type	Annual
Ticker Symbol	JNCE	Meeting Date	12-Jun-2019
Record Date	15-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Luis Diaz, Jr., M.D.		For	For
	2	Barbara Duncan		For	For
	3	Robert Kamen, Ph.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

LABCYTE INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Jan-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Merger	Management	For	For
2	Deemed Conversion of Preferred Stock	Management	For	For
3	Financial Interests of Directors and Officers	Management	For	For
4	Termination of Agreements	Management	For	For
5	General Authority	Management	For	For

LABCYTE INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	16-Jan-2019
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1		Approve Waived Amount to the Executive		Management		For		For

LEXICON PHARMACEUTICALS, INC.

Security	528872302	Meeting Type	Annual
Ticker Symbol	LXRX	Meeting Date	25-Apr-2019
Record Date	25-Feb-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Raymond Debbane		For	For
	2	Robert J. Lefkowitz		For	For
	3	Alan S. Nies		For	For
2.	Ratification and approval of the amendment to the Company’s 2017 Equity Incentive Plan.		Management	For	For
3.	Advisory vote to approve the compensation paid to the Company’s named executive officers.		Management	For	For
4.	Ratification and approval of the appointment of Ernst & Young LLP as Company’s independent auditors for the fiscal year ending December 31, 2019.		Management	For	For

LIGAND PHARMACEUTICALS INCORPORATED

Security	53220K504	Meeting Type	Annual
Ticker Symbol	LGND	Meeting Date	06-Jun-2019
Record Date	10-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jason M. Aryeh		For	For
	2	Todd C. Davis		For	For
	3	Nancy R. Gray, Ph.D.		For	For
	4	John L. Higgins		For	For
	5	John W. Kozarich, Ph.D.		For	For
	6	John L. LaMattina Ph.D.		For	For
	7	Sunil Patel		For	For
	8	Stephen L. Sabba, M.D.		For	For
2.	Ratification of Independent Registered Public Accounting Firm.		Management	For	For
3.	Approval of the Compensation of the Named Executive Officers.		Management	For	For
4.	Approval of Amendment and Restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan.		Management	For	For
5.	Approval of Amendment and Restatement of the Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan		Management	For	For

MADRIGAL PHARMACEUTICALS INC.

Security	558868105	Meeting Type	Annual
Ticker Symbol	MDGL	Meeting Date	27-Jun-2019
Record Date	03-May-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Keith R. Gollust		For	For
	2	Richard S. Levy, M.D.		For	For
	3	David Milligan, Ph.D.		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve our amended 2015 Stock Plan.		Management	For	For
4.	Advisory vote on compensation of named executive officers.		Management	For	For
5.	Frequency of advisory vote on the compensation of named executive officers.		Management	1 Year	For

MARINUS PHARMACEUTICALS, INC.

Security	56854Q101	Meeting Type	Annual
Ticker Symbol	MRNS	Meeting Date	07-May-2019
Record Date	11-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Scott Braunstein		For	For
	2	Seth H.Z. Fischer		For	For
	3	Nicole Vitullo		For	For
2.	The approval of an amendment to our 2014 Plan to increase, on an annual basis, the maximum number of shares of common stock available for issuance under the 2014 Plan by a number of shares equal to the lesser of (i) 5,000,000 shares of common stock, (ii) an amount equal to 4% of the total number of shares of common stock outstanding on such date, or (iii) an amount determined by the Board, each of which may be granted as incentive stock options, and to increase the maximum aggregate number of shares of Company Stock.		Management	Against	Against
3.	The ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

MILESTONE PHARMACEUTICALS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	8-Apr-2019
Record Date	N/A

Item		Proposal		Proposed by		Vote		For/Against Management
1		Designate Michael Tomsicek as an Independent Director		Management		For		For

MILESTONE PHARMACEUTICALS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	26-Apr-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of IPO	Management	For	For
2	Approval of Post-IPO Amendment of Articles of Incorporation	Management	For	For
3	Repeal and Replacement of the By-Laws	Management	For	For
4	Approval of the 2019 Equity Incentive Plan	Management	For	For
5	Approval of the 2019 Employee Share Purchase Plan	Management	For	For
6	Waiver of Registration Rights	Management	For	For
7	Authorization to Call Meetings of Shareholders	Management	For	For
8	Waiver of Transfer Restrictions and Rights of First Refusal	Management	For	For

MIRATI THERAPEUTICS, INC.

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	15-May-2019
Record Date	22-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Charles M. Baum		For	For
	2	Bruce L.A. Carter		For	For
	3	Aaron I. Davis		For	For
	4	Henry J. Fuchs		For	For
	5	Michael Grey		For	For
	6	Faheem Hasnain		For	For
	7	Craig Johnson		For	For
	8	Maya Martinez-Davis		For	For
2.	To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement.		Management	For	For
3.	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.		Management	1 Year	For
4.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019.		Management	For	For
5.	To approve our Amended and Restated 2013 Equity Incentive Plan, to among other things, increase the aggregate number of shares of our common stock authorized for issuance under such plan by 2,500,000 shares.		Management	For	For

MOLECULAR TEMPLATES, INC.

Security	608550109	Meeting Type	Annual
Ticker Symbol	MTEM	Meeting Date	29-May-2019
Record Date	08-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: David Hirsch, M.D., Ph.D.	Management	For	For
1.2	Election of Director: David R. Hoffmann	Management	For	For
1.3	Election of Director: Kevin Lalande	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For
3.	Approve on an advisory basis the compensation of the Company’s named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For
4.	Approve on an advisory basis the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers.	Management	1 Year	For

MYLAN N.V.

Security	N59465109	Meeting Type	Annual
Ticker Symbol	MYL	Meeting Date	21-Jun-2019
Record Date	24-May-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Appointment of Director: Heather Bresch	Management	For	For
1B.	Appointment of Director: Hon. Robert J. Cindrich	Management	For	For
1C.	Appointment of Director: Robert J. Coury	Management	For	For
1D.	Appointment of Director: JoEllen Lyons Dillon	Management	For	For
1E.	Appointment of Director: Neil Dimick, C.P.A.	Management	For	For
1F.	Appointment of Director: Melina Higgins	Management	For	For
1G.	Appointment of Director: Harry A. Korman	Management	For	For
1H.	Appointment of Director: Rajiv Malik	Management	For	For
1I.	Appointment of Director: Richard Mark, C.P.A.	Management	For	For
1J.	Appointment of Director: Mark W. Parrish	Management	For	For
1K.	Appointment of Director: Pauline van der Meer Mohr	Management	For	For
1L.	Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D.	Management	For	For
1M.	Appointment of Director: Sjoerd S. Vollebregt	Management	For	For
2.	Approval, on an advisory basis, of the compensation of the named executive officers of the Company	Management	For	For
3.	Adoption of the Dutch annual accounts for fiscal year 2018	Management	For	For
4.	Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2019	Management	For	For
5.	Instruction to Deloitte Accountants B.V. for the audit of the Company’s Dutch statutory annual accounts for fiscal year 2019	Management	For	For
6.	Authorization of the Board to acquire shares in the capital of the Company	Management	For	For
7.	Delegation to the Board of the authority to issue ordinary shares and grant rights to subscribe for ordinary shares in the capital of the Company and to exclude or restrict pre-emptive rights	Management	For	For
8.	SHAREHOLDER VIEW ON DISCUSSION ITEM ONLY - indication of support for amending Company clawback policy similar to that suggested in the shareholder proposal(Agenda Item 10)	Shareholder	Against

MYOKARDIA, INC.

Security	62857M105	Meeting Type	Annual
Ticker Symbol	MYOK	Meeting Date	13-Jun-2019
Record Date	15-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Sunil Agarwal, M.D.		For	For
	2	Kimberly Popovits		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.		Management	For	For
3.	To recommend, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.		Management	For	For
4.	To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company’s named executive officers.		Management	1 Year	For

NEKTAR THERAPEUTICS

Security	640268108	Meeting Type	Annual
Ticker Symbol	NKTR	Meeting Date	12-Jun-2019
Record Date	15-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: R. Scott Greer	Management	For	For
1b.	Election of Director: Lutz Lingnau	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For
3.	To approve a non-binding advisory resolution regarding our executive compensation (a “say-on-pay” vote).	Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	22-May-2019
Record Date	29-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Richard F. Pops		For	For
	2	Stephen A. Sherwin, M.D		For	For
2.	Advisory vote to approve the compensation paid to the Company’s named executive officers.		Management	For	For
3.	To approve an amendment to the Company’s 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 19,000,000 to 21,000,000.		Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

NOVAVAX, INC.

Security	670002104	Meeting Type	Special
Ticker Symbol	NVAX	Meeting Date	08-May-2019
Record Date	25-Mar-2019

Item		Proposal		Proposed by		Vote		For/Against Management
1.		An amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1-for-20.		Management		For		For

NOVAVAX, INC.

Security	670002104	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	28-Jun-2019
Record Date	02-May-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Rachel K. King		For	For
	2	Michael A. McManus, Jr.		For	For
	3	James F. Young		For	For
2.	To consider and vote whether to approve, on an advisory basis, the compensation paid to our Named Executive Officers.		Management	For	For
3.	To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of the Company’s common stock, par value $0.01, available for issuance thereunder by 1,000,000 shares.		Management	For	For
4.	To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company’s common stock, par value $0.01 available for issuance thereunder by 200,000 shares.		Management	For	For
5.	To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

NOVOCURE LIMITED

Security	G6674U108	Meeting Type	Annual
Ticker Symbol	NVCR	Meeting Date	22-May-2019
Record Date	19-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Jeryl L. Hilleman	Management	For	For
1B.	Election of Director: Kinyip Gabriel Leung	Management	For	For
2.	The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company’s fiscal year ending December 31, 2019.	Management	For	For
3.	A non-binding advisory vote to approve executive compensation.	Management	For	For

OCULIS SA

Security	N/A	Meeting Type	Annual
Ticker Symbol	N/A	Meeting Date	28-Jun-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Approval of Annual Report including Financial Statements	Management	For	For
2	Appropriation of Balance Sheet Results 2018	Management	For	For
3	Discharge of the Members of the Board and Management	Management	For	For
4	Re-Election / Election of the board of Directors	Management	For	For
5	Election of the Auditors	Management	For	For

OVID THERAPEUTICS INC.

Security	690469101	Meeting Type	Annual
Ticker Symbol	OVID	Meeting Date	07-Jun-2019
Record Date	10-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Bart Friedman	Management	For	For
2.	Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

PORTOLA PHARMACEUTICALS, INC.

Security	737010108	Meeting Type	Annual
Ticker Symbol	PTLA	Meeting Date	13-Jun-2019
Record Date	17-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Laura Brege		For	For
	2	Scott Garland		For	For
	3	Hollings Renton		For	For
2.	To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.		Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

PRA HEALTH SCIENCES, INC.

Security	69354M108	Meeting Type	Annual
Ticker Symbol	PRAH	Meeting Date	03-Jun-2019
Record Date	10-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Jeffrey T. Barber		For	For
	2	Linda S. Grais, M.D.		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for 2019.		Management	For	For
3.	Approval, in a non-binding advisory vote, of the compensation paid to the Company’s named executive officers.		Management	For	For

PROTAGONIST THERAPEUTICS INC

Security	74366E102	Meeting Type	Annual
Ticker Symbol	PTGX	Meeting Date	07-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Harold E. Selick, Ph.D.		For	For
	2	Bryan Giraudo		For	For
2.	To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

PTC THERAPEUTICS, INC.

Security	69366J200	Meeting Type	Annual
Ticker Symbol	PTCT	Meeting Date	12-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Allan Jacobson, Ph.D.		For	For
	2	David P. Southwell		For	For
	3	Dawn Svoronos		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	Advisory vote to approve named executive officer compensation.		Management	For	For

PUMA BIOTECHNOLOGY, INC.

Security	74587V107	Meeting Type	Annual
Ticker Symbol	PBYI	Meeting Date	10-Jun-2019
Record Date	22-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Alan H. Auerbach		For	For
	2	Michael P. Miller		For	For
	3	Jay M. Moyes		For	For
	4	Adrian M. Senderowicz		For	For
	5	Troy E. Wilson		For	For
	6	Frank E. Zavrl		For	For
2.	Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2019.		Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.’s named executive officers.		Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	30-Jan-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Authorization and Approval of Note Financing	Management	For	For
2	Waiver of Anti-Dilution Rights	Management	For	For
3	General Authorizing Resolution	Management	For	For

RAINIER THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	23-Apr-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Amendment of Certificate of Incorporation	Management	For	For
2	Amendment and Restatement of 2013 Stock Option and Grant Plan	Management	For	For
3	General Authorizing Resolution	Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	14-Jun-2019
Record Date	17-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Bonnie L. Bassler, Ph.D.	Management	For	For
1b.	Election of Director: Michael S. Brown, M.D.	Management	For	For
1c.	Election of Director: Leonard S. Schleifer, M.D., Ph.D.	Management	For	For
1d.	Election of Director: George D. Yancopoulos, M.D., Ph.D.	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

RHYTHM PHARMACEUTICALS

Security	76243J105	Meeting Type	Annual
Ticker Symbol	RYTM	Meeting Date	19-Jun-2019
Record Date	22-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Jennifer Good	Management	For	For
1.2	Election of Director: Todd Foley	Management	For	For
1.3	Election of Director: Ed Mathers	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2019.	Management	For	For

SAGE THERAPEUTICS, INC.

Security	78667J108	Meeting Type	Annual
Ticker Symbol	SAGE	Meeting Date	05-Jun-2019
Record Date	08-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Kevin P. Starr		For	For
	2	James M. Frates		For	For
	3	George Golumbeski, Ph.D		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To hold a non binding advisory vote to approve the compensation paid to our named executive officers.		Management	For	For

SANGAMO THERAPEUTICS, INC.

Security	800677106	Meeting Type	Annual
Ticker Symbol	SGMO	Meeting Date	10-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	H. Stewart Parker		For	For
	2	Robert F. Carey		For	For
	3	Stephen G. Dilly		For	For
	4	Alexander D. Macrae		For	For
	5	Saira Ramasastry		For	For
	6	Karen L. Smith		For	For
	7	Joseph S. Zakrzewski		For	For
2.	To approve, on an advisory basis, the compensation of the Company’s named executive officers, as described in the Proxy Statement.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019.		Management	For	For

SAREPTA THERAPEUTICS INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	06-Jun-2019
Record Date	11-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A	Election of Director: Richard J. Barry	Management	For	For
1B	Election of Director: M. Kathleen Behrens, Ph.D.	Management	For	For
1C	Election of Director: Claude Nicaise, M.D.	Management	For	For
2.	Advisory Vote To Approve, On A Non-Binding Basis, Named Executive Officer Compensation.	Management	For	For
3.	Approval Of An Amendment To The Amended and Restated 2013 Employee Stock Purchase Plan (The “2013 ESPP”) to Increase the Number of Shares of Common Stock Authorized For Issuance Under the 2013 ESPP by 500,000 Shares to 1,100,000 and To Extend the 2013 ESPP’s Term Until April 22, 2029.	Management	For	For
4.	Ratification Of KPMG LLP As Independent Registered Public Accounting Firm for the Year Ending December 31, 2019.	Management	For	For

SEATTLE GENETICS, INC.

Security	812578102	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	20-May-2019
Record Date	22-Mar-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Srinivas Akkaraju		For	For
	2	Marc Lippman		For	For
	3	Daniel Welch		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
3.	To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2000 Employee Stock Purchase Plan, or the ESPP, to increase the aggregate number of shares of common stock authorized for issuance thereunder by 1,000,000 shares and to allow for the participation in the ESPP by the Company’s non-U.S. based employees.		Management	For	For
4.	Advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.		Management	For	For

SHIRE PLC

Security	82481R106	Meeting Type	Special
Ticker Symbol	SHPG	Meeting Date	05-Dec-2018
Record Date	07-Nov-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve the Scheme of Arrangement.	Management	For	For
2.	Special Resolution: THAT for the purpose of giving effect to the Scheme of Arrangement: (1) the Board of Directors of the Company (the “Board”) be authorized to take all such action as they may consider necessary or appropriate for carrying the Scheme of Arrangement into effect, (2) the articles of association of the Company be amended by the adoption and inclusion of a new Article 154 and (3) conditional upon and with effect from the sanctioning of the Scheme of Arrangement ...(due to space limits, see proxy material for full proposal).	Management	For	For

SPECTRUM PHARMACEUTICALS, INC.

Security	84763A108	Meeting Type	Annual
Ticker Symbol	SPPI	Meeting Date	19-Jun-2019
Record Date	22-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: William L. Ashton	Management	For	For
1.2	Election of Director: Raymond W. Cohen	Management	For	For
1.3	Election of Director: Elizabeth A. Czerepak	Management	For	For
1.4	Election of Director: Joseph W. Turgeon	Management	For	For
1.5	Election of Director: Jeffrey L. Vacirca	Management	For	For
1.6	Election of Director: Dolatrai M. Vyas	Management	For	For
1.7	Election of Director: Bernice R. Welles	Management	For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.	Management	For	For
3.	To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

SUTRO BIOPHARMA, INC.

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	07-Jun-2019
Record Date	16-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Michael Dybbs, Ph.D.		For	For
	2	John G. Freund, M.D.		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For

SYNEOS HEALTH, INC.

Security	87166B102	Meeting Type	Annual
Ticker Symbol	SYNH	Meeting Date	24-May-2019
Record Date	27-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Todd Abbrecht	Management	For	For
1b.	Election of Director: John M. Dineen	Management	For	For
1c.	Election of Director: William E. Klitgaard	Management	For	For
1d.	Election of Director: John Maldonado	Management	For	For
2.	To approve on an advisory (nonbinding) basis our executive compensation.	Management	For	For
3.	To ratify the appointment of the Company’s independent auditors Deloitte & Touche LLP.	Management	For	For

TETRAPHASE PHARMACEUTICALS, INC.

Security	88165N105	Meeting Type	Annual
Ticker Symbol	TTPH	Meeting Date	10-Jun-2019
Record Date	18-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Garen Bohlin		For	For
	2	John Freund		For	For
2.	To amend our 2014 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance under our 2014 Employee Stock Purchase Plan from 300,000 to 600,000.		Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.		Management	For	For
4.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.		Management	For	For

THE MEDICINES COMPANY

Security	584688105	Meeting Type	Annual
Ticker Symbol	MDCO	Meeting Date	30-May-2019
Record Date	11-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Alexander J. Denner	Management	For	For
1B.	Election of Director: Geno J. Germano	Management	For	For
1C.	Election of Director: John C. Kelly	Management	For	For
1D.	Election of Director: Clive A. Meanwell	Management	For	For
1E.	Election of Director: Paris Panayiotopoulos	Management	For	For
1F.	Election of Director: Sarah J. Schlesinger	Management	For	For
1G.	Election of Director: Mark Timney	Management	For	For
2.	Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For

THERACHON AG

Security	N/A	Meeting Type	Ordinary General Meeting
Ticker Symbol	N/A	Meeting Date	8-Apr-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Constitution of the meeting	Management	For	For
2.	Approval of the annual financial statements of the Company for the financial year ended December 31, 2018	Management	For	For
3.	Approval of the appropriation of the financial result 2018	Management	For	For
4.	Approval granting discharge to the members of the board of directors and officers from liability	Management	For	For
5.	Re-election of the board of directors	Management	For	For
6.	Re-election of the auditors	Management	For	For
7.	Approval of an increase of the conditional capital for purposes of employee, director and consultant participation to the amount of up to CHF 126,000, providing for the issuance of up to 4,200,000 registered shared (ordinary shares) with a par value of CHF 0.03 each, and amendment to the articles of association	Management	For	For

THERACHON AG

Security	N/A	Meeting Type	Ordinary General Meeting
Ticker Symbol	N/A	Meeting Date	12-Apr-2019
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Constitution of the meeting	Management	For	For
2.	Approval of interim financial statements of the Company	Management	For	For
3.	Approval of the distribution of a dividend in kind in the form of all shares in the New HoldCo to the shareholders of the Company	Management	For	For
4.	Approval of granting discharge to the members of the board of directors and officers from liability for the period until the Closing Date	Management	For	For
5.	Approval of such other resolutions as may be required or useful in order to approve and give effect to the transactions contemplated by the Business Transfer Agreement or the Share Purchase Agreement	Management	For	For

THERMO FISHER SCIENTIFIC INC.

Security	883556102	Meeting Type	Annual
Ticker Symbol	TMO	Meeting Date	22-May-2019
Record Date	27-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Marc N. Casper	Management	For	For
1b.	Election of Director: Nelson J. Chai	Management	For	For
1c.	Election of Director: C. Martin Harris	Management	For	For
1d.	Election of Director: Tyler Jacks	Management	For	For
1e.	Election of Director: Judy C. Lewent	Management	For	For
1f.	Election of Director: Thomas J. Lynch	Management	For	For
1g.	Election of Director: Jim P. Manzi	Management	For	For
1h.	Election of Director: James C. Mullen	Management	For	For
1i.	Election of Director: Lars R. Sørensen	Management	For	For
1j.	Election of Director: Scott M. Sperling	Management	For	For
1k.	Election of Director: Elaine S. Ullian	Management	For	For
1l.	Election of Director: Dion J. Weisler	Management	For	For
2.	An advisory vote to approve named executive officer compensation.	Management	For	For
3.	Ratification of the Audit Committee’s selection of PricewaterhouseCoopers LLP as the Company’s independent auditors for 2019.	Management	For	For

TRILLIUM THERAPEUTICS INC.

Security	89620X506	Meeting Type	Annual and Special Meeting
Ticker Symbol	TRIL	Meeting Date	27-Jun-2019
Record Date	17-May-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1	DIRECTOR		Management
	1	Mr. Luke Beshar		For	For
	2	Dr. Robert Kirkman		For	For
	3	Dr. Michael Moore		For	For
	4	Dr. Thomas Reynolds		For	For
	5	Dr. Robert Uger		For	For
	6	Dr. Calvin Stiller		For	For
	7	Dr. Helen Tayton-Martin		For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.		Management	For	For
3	To consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set out in the accompanying management information circular dated May 17, 2019, to approve the potential consolidation of the Corporation’s issued and outstanding common shares on the basis of a ratio within a range of one post-consolidation Common Share for every 5 to 30 outstanding pre-consolidation Common Shares, at such time following the date of the Meeting if and as may be determined by the board of directors of the Corporation in its sole discretion, as more particularly described in the Circular.		Management	For	For
4	To consider, and if deemed advisable, to approve, with or without variation, a special resolution, the full text of which is set out in the Circular, to approve the continuance of the Corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act (British Columbia).		Management	For	For

ULTRAGENYX PHARMACEUTICAL INC.

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	11-Jun-2019
Record Date	15-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: William Aliski	Management	For	For
1b.	Election of Director: Lars Ekman, M.D., Ph.D.	Management	For	For
1c.	Election of Director: Matthew K. Fust	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

UNIQURE N.V.

Security	N90064101	Meeting Type	Special
Ticker Symbol	QURE	Meeting Date	24-Oct-2018
Record Date	26-Sep-2018

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Appointment of Robert Gut, M.D. Ph.D as an executive director.		Management		For		For

UNIQURE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	19-Jun-2019
Record Date	22-May-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2018 annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board for their management.	Management	For	For
3.	Re-election of Matthew Kapusta as Executive Director.	Management	For	For
4.	Resolution to reauthorize the Board to issue ordinary shares and options.	Management	For	For
5.	Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares.	Management	For	For
6.	Authorization of the Board to repurchase ordinary shares.	Management	For	For
7.	Resolution to appoint KPMG as external auditor of the Company for the 2019 financial year.	Management	For	For
8.	Advisory approval of compensation of named executive officers.	Management	For	For
9.	Advisory approval on frequency of advisory say on pay votes.	Management	1 Year	Against

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	26-Jun-2019
Record Date	30-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Christopher Causey	Management	For	For
1b.	Election of Director: Richard Giltner	Management	For	For
1c.	Election of Director: Nilda Mesa	Management	For	For
1d.	Election of Director: Judy Olian	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation’s independent registered public accounting firm for 2019.	Management	For	For
5.	Shareholder proposal requesting declassification of the Board of Directors, if properly presented.	Shareholder	For	For

VENITI, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	3-Aug-2018
Record Date	N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	Adoption and Approval of Amendment to Merger Agreement	Management	For	For
2	Waiver of Appraisal and Dissenters’ Rights	Management	For	For
3	Waiver of Notice	Management	For	For
4	Termination of Certain Agreements	Management	For	For
5	Omnibus Resolutions	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	07-May-2019
Record Date	19-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2018.	Management	For	For
O2	To approve the Directors’ Remuneration Report.	Management	For	For
O3	To re-elect Dr. Ken Cunningham as a director of the Company.	Management	For	For
O4	To re-elect Dr. Andrew Sinclair as a director of the Company.	Management	For	For
O5	To re-elect Dr. Martin Edwards as a director of the Company.	Management	For	For
O6	To appoint PricewaterhouseCoopers LLP as auditors.	Management	For	For
O7	To authorise the directors to determine the auditors remuneration.	Management	For	For
O8	To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.	Management	For	For
S9	To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006.	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	05-Jun-2019
Record Date	10-Apr-2019	Holding Recon Date	10-Apr-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Sangeeta Bhatia	Management	For	For
1.2	Election of Director: Lloyd Carney	Management	For	For
1.3	Election of Director: Terrence Kearney	Management	For	For
1.4	Election of Director: Yuchun Lee	Management	For	For
1.5	Election of Director: Jeffrey Leiden	Management	For	For
1.6	Election of Director: Bruce Sachs	Management	For	For
2.	Amendment and restatement of our 2013 Stock and Option Plan to, among other things, increase the number of shares available under the plan by 5.0 million shares.	Management	For	For
3.	Amendment and restatement of our 2013 Employee Stock Purchase Plan to, among other things, increase the number of shares available under the plan by 2.0 million shares.	Management	For	For
4.	Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2019.	Management	For	For
5.	Advisory vote on named executive officer compensation.	Management	For	For
6.	Shareholder proposal, if properly presented at the meeting, requesting annual reporting on the integration of risks relating to drug prices into our executive compensation program.	Shareholder	Against	For
7.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.	Shareholder	Against	For

VIKING THERAPEUTICS INC

Security	92686J106	Meeting Type	Annual
Ticker Symbol	VKTX	Meeting Date	23-May-2019
Record Date	01-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Matthew W. Foehr		For	For
	2	Charles A. Rowland, Jr.		For	For
2.	Ratification of the selection of MARCUM LLP as the Company’s Independent Registered Public Account Firm for its fiscal year ending December 31, 2019.		Management	For	For

XENCOR INC

Security	98401F105	Meeting Type	Annual
Ticker Symbol	XNCR	Meeting Date	26-Jun-2019
Record Date	29-Apr-2019

Item	Proposal		Proposed by	Vote	For/Against Management
1.	DIRECTOR		Management
	1	Dr. Kevin C. Gorman		For	For
	2	Dr. A Bruce Montgomery		For	For
	3	Dr. Bassil I. Dahiyat		For	For
	4	Mr. Kurt Gustafson		For	For
	5	Mr. Yujiro S. Hata		For	For
	6	Mr. Richard Ranieri		For	For
	7	Dr. Ellen G. Feigal		For	For
2.	Proposal to ratify RSM US LLP as the independent public accounting firm for 2019		Management	For	For
3.	Proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy materials		Management	For	For

ZOGENIX, INC.

Security	98978L204	Meeting Type	Annual
Ticker Symbol	ZGNX	Meeting Date	22-May-2019
Record Date	26-Mar-2019

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Erle T. Mast	Management	For	For
1B.	Election of Director: Renee P. Tannenbaum, Pharm D.	Management	For	For
2.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Management	For	For
4.	Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000.	Management	For	For
5.	Approval of an amendment and restatement of the Company’s 2010 Equity Incentive Award Plan.	Management	Against	Against

Security	151020104	Meeting Type	Special
Ticker Symbol	CELG	Meeting Date	12-Apr-2019
Record Date	01-Mar-2019

(Registrant)		Tekla Life Sciences Investors

By (Signature and Title)*

			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)

Date	8/15/19